Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Ehsan Rahimy, MD, a retina specialist at Palo Alto Medical Foundation, discussed promising advancements in the treatment of retinal diseases.
Rahimy said there was a plethora of real-world data published in 2025 on switching patients who had an incomplete or suboptimal response to certain anti-VEGF therapies to “more durable” next-generation therapies, such as Eylea HD (aflibercept 8 mg, Regeneron).
“I’ve been encouraged to see that patients on average have been able to extend treatment intervals out to about 2 to 3 weeks